← Back to Screener
Achieve Life Sciences, Inc. (ACHV)
Price$4.25
Favorite Metrics
Price vs S&P 500 (26W)56.84%
Price vs S&P 500 (4W)18.01%
Market Capitalization$226.27M
All Metrics
Book Value / Share (Quarterly)$0.40
P/TBV (Annual)12.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-44.67%
Cash Flow / Share (Quarterly)$-0.93
Price vs S&P 500 (YTD)-1.52%
Net Profit Margin (TTM)-94.67%
EPS (TTM)$-1.29
10-Day Avg Trading Volume2.38M
EPS Excl Extra (TTM)$-1.29
Revenue Growth (5Y)-1.65%
EPS (Annual)$-1.25
ROI (Annual)-150.10%
Gross Margin (Annual)-98.76%
Net Profit Margin (5Y Avg)-159.73%
Cash / Share (Quarterly)$0.68
ROA (Last FY)-130.77%
Revenue Growth TTM (YoY)-89.25%
EBITD / Share (TTM)$-1.26
ROE (5Y Avg)-222.50%
Operating Margin (TTM)-106.51%
Cash Flow / Share (Annual)$-0.93
P/B Ratio10.52x
P/B Ratio (Quarterly)12.30x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)12.36x
Net Interest Coverage (TTM)-88.50x
ROA (TTM)-121.36%
EPS Incl Extra (Annual)$-1.25
Current Ratio (Annual)4.39x
Quick Ratio (Quarterly)4.01x
3-Month Avg Trading Volume0.84M
52-Week Price Return141.71%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.39
P/S Ratio (Annual)44.72x
Asset Turnover (Annual)0.18x
52-Week High$6.03
Operating Margin (5Y Avg)-175.65%
EPS Excl Extra (Annual)$-1.25
CapEx CAGR (5Y)-31.57%
Tangible BV CAGR (5Y)5.41%
26-Week Price Return65.58%
Quick Ratio (Annual)4.01x
13-Week Price Return-9.09%
Total Debt / Equity (Annual)0.69x
Current Ratio (Quarterly)4.39x
Enterprise Value$220.23
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)-49.48%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-397.83%
Cash / Share (Annual)$0.68
3-Month Return Std Dev109.74%
Gross Margin (5Y Avg)-120.50%
Net Income / Employee (TTM)$-2
ROE (Last FY)-253.96%
Net Interest Coverage (Annual)-95.08x
EPS Basic Excl Extra (Annual)$-1.25
P/FCF (TTM)37.40x
Receivables Turnover (TTM)20.24x
Total Debt / Equity (Quarterly)0.69x
EPS Incl Extra (TTM)$-1.29
Receivables Turnover (Annual)20.65x
ROI (TTM)-144.23%
P/S Ratio (TTM)12.70x
Pretax Margin (5Y Avg)-159.73%
Revenue / Share (Annual)$506.00
Tangible BV / Share (Annual)$0.39
Price vs S&P 500 (52W)106.61%
Year-to-Date Return2.62%
5-Day Price Return42.46%
EPS Normalized (Annual)$-1.25
ROA (5Y Avg)-119.77%
Net Profit Margin (Annual)-397.83%
Month-to-Date Return73.47%
EBITD / Share (Annual)$-1.26
Operating Margin (Annual)-418.77%
LT Debt / Equity (Annual)0.52x
ROI (5Y Avg)-114.02%
LT Debt / Equity (Quarterly)0.52x
EPS Basic Excl Extra (TTM)$-1.29
P/TBV (Quarterly)12.74x
P/B Ratio (Annual)12.30x
Pretax Margin (TTM)-94.67%
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)-11.96%
Beta2.45x
P/FCF (Annual)6.49x
Revenue / Share (TTM)$212.00
ROE (TTM)-204.14%
52-Week Low$1.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.08
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.25 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $583.06 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.97 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 295.25x | -5.72% | 89.00% | — | $26.98 |
CLDXCelldex Therapeutics, Inc | 1753.49x | -77.98% | 17.65% | — | $34.38 |
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.63 |
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.21 |
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.89 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $2.91 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 31.65x | 115.58% | 56.97% | — | $3.99 |
About
Achieve Life Sciences is a specialty pharmaceutical company developing and commercializing cytisinicline, an established smoking cessation treatment approved in Central and Eastern Europe. The company aims to expand cytisinicline's availability as a treatment for nicotine addiction and address the global smoking health epidemic.